CN101835463A - 环孢菌素组合物 - Google Patents

环孢菌素组合物 Download PDF

Info

Publication number
CN101835463A
CN101835463A CN200880113223A CN200880113223A CN101835463A CN 101835463 A CN101835463 A CN 101835463A CN 200880113223 A CN200880113223 A CN 200880113223A CN 200880113223 A CN200880113223 A CN 200880113223A CN 101835463 A CN101835463 A CN 101835463A
Authority
CN
China
Prior art keywords
compositions
cyclosporin
new zealand
zealand white
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880113223A
Other languages
English (en)
Chinese (zh)
Inventor
R·S·格雷厄姆
W·L·提恩
A·摩根
R·希夫曼
D·A·霍兰德
M·阿塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN101835463A publication Critical patent/CN101835463A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN200880113223A 2007-09-20 2008-09-18 环孢菌素组合物 Pending CN101835463A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/858,200 2007-09-20
US11/858,200 US20080146497A1 (en) 2006-07-25 2007-09-20 Cyclosporin Compositions
PCT/US2008/076756 WO2009099467A2 (en) 2007-09-20 2008-09-18 Cyclosporin compositions

Publications (1)

Publication Number Publication Date
CN101835463A true CN101835463A (zh) 2010-09-15

Family

ID=39528114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880113223A Pending CN101835463A (zh) 2007-09-20 2008-09-18 环孢菌素组合物

Country Status (12)

Country Link
US (1) US20080146497A1 (enExample)
EP (1) EP2190407B1 (enExample)
JP (1) JP2010540446A (enExample)
KR (1) KR20100091946A (enExample)
CN (1) CN101835463A (enExample)
AU (1) AU2008349774A1 (enExample)
BR (1) BRPI0816995A2 (enExample)
CA (1) CA2700182A1 (enExample)
IL (1) IL204614A0 (enExample)
MX (1) MX2010003045A (enExample)
RU (1) RU2010112472A (enExample)
WO (1) WO2009099467A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
MX2010003364A (es) 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
WO2010127301A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Method of treating allergic conjunctivitis with cyclosporin compositions
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
RU2014129268A (ru) * 2011-12-16 2016-02-10 Аллерган, Инк. Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
FR2988297B1 (fr) * 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
EP3169308B1 (en) * 2014-07-18 2021-01-27 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
RU2762767C1 (ru) * 2020-09-15 2021-12-22 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Министерства здравоохранения Российской Федерации Способ определения тактильной чувствительности роговицы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
EP1301210A2 (en) * 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
PL1904056T3 (pl) * 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組

Also Published As

Publication number Publication date
EP2190407B1 (en) 2016-12-07
EP2190407A2 (en) 2010-06-02
WO2009099467A3 (en) 2009-10-22
IL204614A0 (en) 2010-11-30
CA2700182A1 (en) 2009-08-13
KR20100091946A (ko) 2010-08-19
MX2010003045A (es) 2010-04-29
BRPI0816995A2 (pt) 2015-03-24
JP2010540446A (ja) 2010-12-24
RU2010112472A (ru) 2011-10-27
AU2008349774A1 (en) 2009-08-13
US20080146497A1 (en) 2008-06-19
WO2009099467A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
CN101835463A (zh) 环孢菌素组合物
US20220409693A1 (en) Cyclosporin compositions
US20220265631A1 (en) Ophthalmic composition
RU2330668C2 (ru) Применение римексолона для лечения синдрома сухого глаза
TWI324925B (en) Ophthalmic composition
JP2005508866A (ja) ヒアルロン酸を含んでなる眼用組成物
JPWO2016190306A1 (ja) 水性眼科組成物
CN103764120A (zh) 聚乙二醇15羟基硬脂酸酯制剂
CN102716074A (zh) 一种贝美前列素滴眼剂及其制备方法
Gangrade et al. Topical ophthalmic formulations: basic considerations
CN101896160A (zh) 环胞菌素组合物
AU2016203191B2 (en) Cyclosporin compositions
AU2022202326A1 (en) Cyclosporin compositions
WO2002100436A2 (en) Ophthalmic once-a-day composition
HK1146893A (en) Cyclosporin compositions
JP2022130153A (ja) 医薬製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100915